New Study Findings from University College London (UCL) Hospitals NHS Foundation Trust Illuminate Research in Anemia [Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and...].

A recent study conducted by University College London (UCL) Hospitals NHS Foundation Trust has investigated the use of SAR445088 (BIVV020) as a potential treatment for cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia. SAR445088 is a second-generation complement inhibitor that selectively inhibits the activated form of C1s. The study found that SAR445088 was generally well-tolerated and led to classical complement inhibition, control of hemolysis, and improvement in anemia, which was sustained for 15 weeks. These findings suggest that SAR445088 may be a promising treatment option for patients with CAD. [Extracted from the article]